Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news